Vifor Pharma AG
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
333 / 1328
Position in country
111 / 449
Return on Assets, %
5.2
-2.7
Net income margin, %
9.2
2.8
EBITDA margin, %
35.7
10.8
Debt to Equity, %
17.2
19.2
Intangible assets and goodwill, %
46.7
3.6
Revenue CAGR 3Y, %
3.4
8.5
Revenue Y, % chg
0
0.5
P/BV
9.5
1.5
EV/EBITDA
17.8
7.4
Dividend Yield, %
1.2
1.7
Payout Ratio, %
88.5
30.3
Dividend Ex Date
2022-04-29
Competitors
Ranks
-
Novo Nordisk A/S
00%
-
Vifor Pharma AG
00%
-
AstraZeneca PLC
00%
-
Eli Lilly and Co
00%
-
Roche Holding AG
00%
-
Dottikon Es Holding AG
00%
-
Novartis AG
00%
-
Sandoz Group AG
00%
-
Johnson & Johnson
00%
-
Merck & Co Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Switzerland
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
11600.1
Ticker
VIFN.S
ISIN
CH0364749348
IPO date
Availability on Russian exchanges
No
Reporting for
2022-02-17
Date fact. publication of reports
2021-12-31
Company Description
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: